BNP Paribas Financial Markets Lowers Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

BNP Paribas Financial Markets lowered its stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 39.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,205 shares of the medical instruments supplier's stock after selling 2,792 shares during the period. BNP Paribas Financial Markets' holdings in ICU Medical were worth $652,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Harvest Fund Management Co. Ltd purchased a new position in ICU Medical in the fourth quarter worth about $33,000. Quarry LP raised its holdings in ICU Medical by 764.3% in the 4th quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock worth $38,000 after acquiring an additional 214 shares during the last quarter. Murphy & Mullick Capital Management Corp bought a new position in ICU Medical in the 4th quarter valued at approximately $52,000. Venturi Wealth Management LLC boosted its stake in ICU Medical by 64.0% during the 4th quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier's stock valued at $82,000 after purchasing an additional 206 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of ICU Medical by 88.8% in the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 300 shares in the last quarter. Institutional investors own 96.10% of the company's stock.

ICU Medical Stock Performance

ICUI stock traded up $1.45 during trading on Tuesday, reaching $130.44. The stock had a trading volume of 297,270 shares, compared to its average volume of 277,557. ICU Medical, Inc. has a 52 week low of $100.91 and a 52 week high of $196.26. The stock's 50 day moving average is $139.22 and its two-hundred day moving average is $152.03. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The firm has a market cap of $3.21 billion, a PE ratio of -28.54 and a beta of 0.87.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, beating the consensus estimate of $1.23 by $0.49. The firm had revenue of $599.49 million during the quarter, compared to analyst estimates of $574.15 million. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The business's revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.96 EPS. As a group, equities analysts anticipate that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Insider Activity

In other ICU Medical news, Director David C. Greenberg sold 1,942 shares of ICU Medical stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total transaction of $278,987.72. Following the transaction, the director now owns 6,760 shares of the company's stock, valued at $971,141.60. The trade was a 22.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elisha W. Finney sold 600 shares of the stock in a transaction on Monday, May 19th. The stock was sold at an average price of $138.92, for a total transaction of $83,352.00. Following the completion of the sale, the director now directly owns 3,252 shares of the company's stock, valued at approximately $451,767.84. This trade represents a 15.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,167 shares of company stock valued at $3,571,788 in the last 90 days. Company insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

ICUI has been the subject of several research analyst reports. KeyCorp reduced their price objective on ICU Medical from $209.00 to $191.00 and set an "overweight" rating for the company in a report on Monday, April 21st. Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a report on Tuesday, April 8th. Wall Street Zen raised shares of ICU Medical from a "hold" rating to a "buy" rating in a report on Sunday, May 18th. Finally, Raymond James lowered their price objective on shares of ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a research report on Friday, May 9th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $192.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.